Blog
Follow us for the latest trends, insights and innovations in the pharmaceutical industry.
High-Purity Diabetes Drug Intermediates | SGLT2, GLP-1 & Orforglipron
It clarifies the core differences between SGLT2 inhibitors and GLP-1 receptor agonists, covering their mechanisms, clinical advantages and representative products. It highlights Orforglipron, a breakthrough ...
Read More →
Essential Documentation for Regulatory Submission of Intermediates (DMF/CEP)
Master regulatory submission for pharmaceutical intermediates with DMF/CEP documentation best practices. Fix common deficiencies, align with FDA/EDQM guidelines, and streamline review processes.
Read More →
Hydrogenation in Pharmaceutical Intermediates: Risks and Solutions
This article breaks down 4 core risks with authoritative industry data, and shares full-process, FDA & ICH-aligned solutions to reduce accidents, improve yields and ensure ...
Read More →
Technology Transfer Pitfalls in Intermediate Projects: Avoid Costly Mistakes
This article breaks down the 4 most costly mistakes — including incomplete documentation and ignored scalability — with verified industry data and real cases.
Read More →